ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2024, Vol. 38 ›› Issue (1): 128-137.doi: 10.6040/j.issn.1673-3770.0.2022.535
• Review • Previous Articles Next Articles
LIU Tianwei1, ZHAO Bojun2
CLC Number:
| [1] Nalcaci S, Degirmenci C, Akkin C, et al. Etiological factors in young patients with Retinal Vein Occlusion[J]. Pak J Med Sci, 2019, 35(5): 1397-1401. doi:10.12669/pjms.35.5.546 [2] Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders[J]. Prog Retin Eye Res, 2005, 24(4): 493-519. doi:10.1016/j.preteyeres.2004.12.001 [3] Chen TY, Uppuluri A, Zarbin MA, et al. Risk factors for central retinal vein occlusion in young adults[J]. Eur J Ophthalmol, 2021, 31(5): 2546-2555. doi:10.1177/1120672120960333 [4] Dewan KS, Hentati F, Greenlee TE, et al. Age-related differences in presentation and outcomes of anti-VEGF treatment of retinal vein occlusion[J]. Can J Ophthalmol, 2021, 56(2): 96-104. doi:10.1016/j.jcjo.2020.09.004 [5] Eah KS, Kim YN, Park YJ, et al. Central retinal vein occlusion in young patients: clinical characteristics and prognostic factors[J]. Retina, 2021, 41(3): 630-637. doi:10.1097/IAE.0000000000002872 [6] Yau JW, Lee P, Wong TY, et al. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management[J]. Intern Med J, 2008, 38(12): 904-910. doi:10.1111/j.1445-5994.2008.01720.x [7] Sanlés González I, Napal Lecumberri JJ, Pérez-Montes R, et al. Retinal vein occlusion in patients under 50 years. Analysis of vascular risk factors, thrombophilia, carotid ultrasound findings and uncommon aetiologies[J]. Arch Soc Esp Oftalmol(Engl Ed), 2022, 97(8): 443-449. doi:10.1016/j.oftale.2021.12.002 [8] Hirano Y, Suzuki N, Tomiyasu T, et al. Multimodal imaging of microvascular abnormalities in retinal vein occlusion[J]. J Clin Med, 2021, 10(3): 405. doi:10.3390/jcm10030405 [9] Cunha-Vaz J. Mechanisms of retinal fluid accumulation and blood-retinal barrier breakdown[J]. Dev Ophthalmol, 2017, 58: 11-20. doi:10.1159/000455265 [10] Noma H, Yasuda K, Shimura M. Cytokines and the pathogenesis of macular edema in branch retinal vein occlusion[J]. J Ophthalmol, 2019: 5185128. doi:10.1155/2019/5185128 [11] Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal vein occlusion[J]. J Clin Med, 2020, 9(11): 3457. doi:10.3390/jcm9113457 [12] Jung SH, Kim KA, Sohn SW, et al. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion[J]. Invest Ophthalmol Vis Sci, 2014, 55(4): 2290-2296. doi:10.1167/iovs.13-13587 [13] Lee WJ, Kang MH, Seong M, et al. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion[J]. Br J Ophthalmol, 2012, 96(11): 1426-1430. doi:10.1136/bjophthalmol-2012-301913 [14] Noma H, Mimura T, Yasuda K, et al. Role of soluble vascular endothelial growth factor receptors-1 and-2, their ligands, and other factors in branch retinal vein occlusion with macular edema[J]. Invest Ophthalmol Vis Sci, 2014, 55(6): 3878-3885. doi:10.1167/iovs.14-13961 [15] Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia[J]. Ophthalmology, 2010, 117(2): 313-319.e1. doi:10.1016/j.ophtha.2009.07.017 [16] Song PG, Xu YH, Zha MM, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors[J]. J Glob Health, 2019, 9(1): 010427. doi:10.7189/jogh.09.010427 [17] Chang YS, Ho CH, Chu CC, et al. Risk of retinal vein occlusion in patients with diabetes mellitus: a retrospective cohort study[J]. Diabetes Res Clin Pract, 2021, 171: 108607. doi:10.1016/j.diabres.2020.108607 [18] Pacella F, Bongiovanni G, Malvasi M, et al. Impact of cardiovascular risk factors on incidence and severity of Retinal Vein Occlusion[J]. Clin Ter, 2020, 171(6): e534-e538. doi:10.7417/CT.2020.2269 [19] Kujovich JL. Factor V leiden thrombophilia[J]. Genet Med, 2011, 13(1): 1-16. doi:10.1097/GIM.0b013e3181faa0f2 [20] Rothman AL, Thomas AS, Khan K, et al. Central retinal vein occlusion in young individuals: a comparison of risk factors and clinical outcomes[J]. Retina, 2019, 39(10): 1917-1924. doi:10.1097/IAE.0000000000002278 [21] Varga EA, Sturm AC, Misita CP, et al. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease[J]. Circulation, 2005, 111(19): e289-e293. doi:10.1161/01.CIR.0000165142.37711.E7 [22] Bucciarelli P, Passamonti SM, Gianniello F, et al. Thrombophilic and cardiovascular risk factors for retinal vein occlusion[J]. Eur J Intern Med, 2017, 44: 44-48. doi:10.1016/j.ejim.2017.06.022 [23] Bharathi Devi SR, Suganeswari G, Sharma T, et al. Homocysteine induces oxidative stress in young adult central retinal vein occlusion[J]. Br J Ophthalmol, 2012, 96(8): 1122-1126. doi:10.1136/bjophthalmol-2011-301370 [24] Goh EJH, Goh KY. An unusual case of concurrent central retinal vein and cilioretinal artery occlusion in a healthy patient[J]. Case Rep Ophthalmol, 2021, 12(2): 407-411. doi:10.1159/000513794 [25] Sedlak L, Swierczyńska M, Pojda-Wilczek D. Combined central retinal vein and cilioretinal artery occlusion in a 25-year-old woman [J]. Rom J Ophthalmol, 2022, 66(2): 178-184.. doi: 10.22336/rjo.2022.35 [26] Sinawat S, Bunyavee C, Ratanapakorn T, et al. Systemic abnormalities associated with retinal vein occlusion in young patients[J]. Clin Ophthalmol, 2017, 11: 441-447. doi:10.2147/OPTH.S128341 [27] Romiti GF, Corica B, Borgi M, et al. Inherited and acquired thrombophilia in adults with retinal vascular occlusion: a systematic review and meta-analysis[J]. J Thromb Haemost, 2020, 18(12): 3249-3266. doi:10.1111/jth.15068 [28] Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M,et al. Coagulation disorders and the risk of retinal vein occlusion[J]. Thromb Haemost, 2010, 103(2): 299-305. doi:10.1160/TH09-05-0331 [29] Borgman CJ. Concomitant multiple myeloma spectrum diagnosis in a central retinal vein occlusion: a case report and review[J]. Clin Exp Optom, 2016, 99(4): 309-312. doi:10.1111/cxo.12319 [30] Dammacco R, Lisch W, Kivelä TT, et al. The spectrum of ocular manifestations in patients with waldenström's macroglobulinemia[J]. Ocul Immunol Inflamm, 2022, 30(7/8): 1659-1668. doi:10.1080/09273948.2021.1933068 [31] Yang V, Turner LD, Imrie F. Central retinal vein occlusion secondary to severe iron-deficiency anaemia resulting from a plant-based diet and menorrhagia: a case presentation[J]. BMC Ophthalmol, 2020, 20(1): 112. doi:10.1186/s12886-020-01372-6 [32] Huggins AB, Garg SJ, Sando RS. Central retinal vein occlusion in hereditary spherocytosis[J]. RETINAL Cases Brief Rep, 2015, 13. doi:10.1097/icb.0000000000000247 [33] Kumar A, Shankar S, Kochhar D, et al. Acute myeloid leukemia presenting as unilateral central retinal vein occlusion[J]. GMS Ophthalmol Cases, 2022, 12: Doc15. doi:10.3205/oc000202 [34] Caprini JA, Glase CJ, Anderson CB, et al. Laboratory markers in the diagnosis of venous thromboembolism[J]. Circulation, 2004, 109(12 Suppl 1): I4-I8. doi:10.1161/01.CIR.0000122869.59485.36 [35] Zhu W, Wu Y, Xu M, et al. Antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis[J]. PLoS One, 2014, 10(4): e0122814. doi:10.1371/journal.pone.0122814 [36] João MD, Costa JV, Santos GC, et al. Retinal vein and artery occlusion as the first manifestation of primary antiphospholipid syndrome in a pediatric patient[J]. Arq Bras Oftalmol, 2022: S0004-S27492022005008207. doi:10.5935/0004-2749.2021-0431 [37] Yen YC, Weng SF, Chen HA, et al. Risk of retinal vein occlusion in patients with systemic lupus erythematosus: a population-based cohort study[J]. Br J Ophthalmol, 2013, 97(9): 1192-1196. doi:10.1136/bjophthalmol-2013-303265 [38] Nag TC, Wadhwa S. Vascular changes of the retina and choroid in systemic lupus erythematosus: pathology and pathogenesis[J]. Curr Neurovasc Res, 2006, 3(2): 159-168. doi:10.2174/156720206776875821 [39] Dunn JP, Yamashita A, Kempen JH, et al. Retinal vascular occlusion in patients infected with human immunodeficiency virus[J]. Retina, 2005, 25(6): 759-766. doi:10.1097/00006982-200509000-00012 [40] Mahyudin M, Choo MM, Ramli NM, et al. Ocular tuberculosis initially presenting as central retinal vein occlusion[J]. Case Rep Ophthalmol, 2010, 1(1): 30-35. doi:10.1159/000317605 [41] O'Donovan C, Vyas N, Ghanchi F. Retinal vein occlusion with COVID-19: a case report and review of literature[J]. Ocul Immunol Inflamm, 2022. doi:10.1080/09273948.2022.2032196 [42] Takacs A, Ecsedy M, Nagy ZZ. Possible COVID-19 MRNA vaccine-induced case of unilateral central retinal vein occlusion[J]. Ocul Immunol Inflamm, 2022. doi:10.1080/09273948.2022.2094811 [43] Feltgen N, Ach T, Ziemssen F, et al. Retinal vascular occlusion after COVID-19 vaccination: more coincidence than causal relationship? data from a retrospective multicentre study[J]. J Clin Med, 2022, 11(17): 5101. doi:10.3390/jcm11175101 [44] Nicolo' M, Artioli S, La Mattina GC, et al. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin[J]. Eur J Ophthalmol, 2005, 15(6): 811-814. doi:10.5301/EJO.2008.4623 [45] Moussa O, Chen RWS. Central retinal vein occlusion associated with creatine supplementation and dehydration[J]. Am J Ophthalmol Case Rep, 2021, 23: 101128. doi:10.1016/j.ajoc.2021.101128 [46] Prabhudesai A, Shetty S, Ghosh K, et al. Multiple heritable and acquired risk factors in a case of recurrent retinal vein occlusion[J]. J Assoc Physicians India, 2018, 66(3): 81-83 [47] Aggarwal RS, Mishra VV, Aggarwal SV. Oral contraceptive pills: a risk factor for retinal vascular occlusion in in-vitro fertilization patients[J]. J Hum Reprod Sci, 2013, 6(1): 79-81. doi:10.4103/0974-1208.112389 [48] Ha MJ, Han K, Jung Y, et al. Is retinal vein occlusion associated with depression symptoms?: a nationwide cohort study[J]. Medicine(Baltimore), 2021, 100(32): e26937. doi:10.1097/MD.0000000000026937 [49] Yin X, Li JQ, Zhang BY, et al. Association of glaucoma with risk of retinal vein occlusion: a meta-analysis[J]. Acta Ophthalmol, 2019, 97(7): 652-659. doi:10.1111/aos.14141 [50] Xu K, Wu LL, Ma ZZ, et al. Primary angle closure and primary angle closure glaucoma in retinal vein occlusion[J]. Acta Ophthalmol, 2019, 97(3): e364-e372. doi:10.1111/aos.13879 [51] Kim MJ, Woo SJ, Park KH, et al. Retinal nerve fiber layer thickness is decreased in the fellow eyes of patients with unilateral retinal vein occlusion[J]. Ophthalmology, 2011, 118(4): 706-710. doi:10.1016/j.ophtha.2010.08.028 [52] Kim YN, Shin JW, Park YJ, et al. Glaucoma as a prognostic factor of central retinal vein occlusion: visual and anatomical outcomes and occurrence of ischaemic central retinal vein occlusion[J]. Acta Ophthalmol, 2021, 99(4): e523-e530. doi:10.1111/aos.14608 [53] Ghoghari H, Rizvi SF, Loya H, et al. Axial length, a risk factor for retinal vein occlusion: a case control study[J]. J Pak Med Assoc, 2019, 69(12): 1800-1802. doi:10.5455/JPMA.6579 [54] Szigeti A, Schneider M, Ecsedy M, et al. Association between retinal vein occlusion, axial length and vitreous chamber depth measured by optical low coherence reflectometry[J]. BMC Ophthalmol, 2015, 15: 45. doi:10.1186/s12886-015-0031-1 [55] Satoh S, Itoh C, Nakamura N. A case of frosted branch angiitis associated with retinal vein occlusion as a complication of familial Mediterranean fever[J]. Nippon Ganka Gakkai Zasshi, 2010, 114(7): 621-628 [56] Vofo BN, Amer R. Outer retina rupture from subretinal blood with spontaneous sealing and visual recovery in frosted branch angiitis from familial Mediterranean fever: a case report[J]. Turk J Ophthalmol, 2022, 52(4): 286-290. doi:10.4274/tjo.galenos.2022.69337 [57] Sarpangala S, George NM, Kamath YS, et al. Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic - A case report[J]. Indian J Ophthalmol, 2021, 69(9): 2532-2535. doi:10.4103/ijo.IJO_1644_21 [58] Kopsachilis N, Brar M, Marinescu AI, et al. Central nervous system tuberculosis presenting as branch retinal vein occlusion[J]. Clin Exp Optom, 2013, 96(1): 121-123. doi:10.1111/j.1444-0938.2012.00757.x [59] Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion[J]. Ophthalmology, 2011, 118(1): 119-133.e1-2. doi:10.1016/j.ophtha.2010.04.019 [60] Hayreh SS. Photocoagulation for retinal vein occlusion[J]. Prog Retin Eye Res, 2021, 85: 100964. doi:10.1016/j.preteyeres.2021.100964 [61] Browning DJ. Patchy ischemic retinal whitening in acute central retinal vein occlusion[J]. Ophthalmology, 2002, 109(11): 2154-2159. doi:10.1016/s0161-6420(02)01217-4 [62] Ye PP, Zhu TP, Zheng F, et al. Microvascular comparison in younger and older patients with retinal vein occlusion analyzed by OCT angiography[J]. BMC Ophthalmol, 2021, 21(1): 161. doi:10.1186/s12886-021-01931-5 [63] Paques M, Tadayoni R, Sercombe R, et al. Structural and hemodynamic analysis of the mouse retinal microcirculation[J]. Invest Ophthalmol Vis Sci, 2003, 44(11): 4960-4967. doi:10.1167/iovs.02-0738 [64] Bonnin S, Mané V, Couturier A, et al. New insight into the macular deep vascular plexus imaged by optical coherence tomography angiography[J]. Retina, 2015, 35(11): 2347-2352. doi:10.1097/IAE.0000000000000839 [65] Aref AA, Scott IU, VanVeldhuisen PC, et al. Intraocular pressure-related events after anti-vascular endothelial growth factor therapy for macular edema due to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 report 16 on a secondary analysis of a randomized clinical trial[J]. JAMA Ophthalmol, 2021, 139(12): 1285-1291. doi:10.1001/jamaophthalmol.2021.4395 [66] Scott IU, Oden NL, VanVeldhuisen PC, et al. Baseline characteristics and outcomes after anti-vascular endothelial growth factor therapy for macular edema in participants with hemiretinal vein occlusion compared with participants with central retinal vein occlusion: study of comparative treatments for retinal vein occlusion 2(SCORE2)report 18[J]. JAMA Ophthalmol, 2022, 140(5): 458-464. doi:10.1001/jamaophthalmol.2022.0352 [67] Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study[J]. Am J Ophthalmol, 2010, 150(3): 310-314. doi:10.1016/j.ajo.2010.03.028 [68] 韩克阳, 于贝贝, 赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131. doi:10.6040/j.issn.1673-3770.0.2017.515 HAN Keyang, YU Beibei, ZHAO Bojun. Morphological structure analysis of the macular area after anti-VEGF treatment for short-term retinal vein occlusion[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 129-131. doi:10.6040/j.issn.1673-3770.0.2017.515 [69] Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study[J]. Ophthalmology, 2010, 117(6): 1102-1112.e1. doi:10.1016/j.ophtha.2010.02.021 [70] Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study[J]. Ophthalmology, 2010, 117(6): 1124-1133.e1. doi:10.1016/j.ophtha.2010.02.022 [71] Scott IU, VanVeldhuisen PC, Ip MS, et al. Baseline factors associated with 6-month visual acuity and retinal thickness outcomes in patients with macular edema secondary to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 study report 4[J]. JAMA Ophthalmol, 2017, 135(6): 639-649. doi:10.1001/jamaophthalmol.2017.1141 [72] Spooner K, Fraser-Bell S, Hong T, et al. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab[J]. Clin Exp Ophthalmol, 2020, 48(1): 53-60. doi:10.1111/ceo.13636 [73] Vader MJC, Schauwvlieghe AME, Verbraak FD, et al. Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: the bevacizumab to ranibizumab in retinal vein occlusions(BRVO)study, a randomized trial[J]. Ophthalmol Retina, 2020, 4(6): 576-587. doi:10.1016/j.oret.2019.12.019 [74] Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion[J]. Ophthalmology, 2010, 117(6): 1134-1146.e3. doi:10.1016/j.ophtha.2010.03.032 [75] Rezkallah A, Mathis T, Abukhashabah A, et al. Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections: the safodex-2 study[J]. Retina, 2021, 41(7): 1438-1445. doi:10.1097/IAE.0000000000003080 [76] Battaglia Parodi M, Iacono P, Sacconi R, et al. Dexamethasone implant for macular edema secondary to central retinal vein occlusion in patients younger than 50 years[J]. Retina, 2015, 35(7): 1381-1386. doi:10.1097/IAE.0000000000000494 [77] Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results[J]. Ophthalmology, 2011, 118(12): 2453-2460. doi:10.1016/j.ophtha.2011.05.014 [78] Georgalas L, Tservakis I, Kiskira EE, et al. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study[J]. Cutan Ocul Toxicol, 2019, 38(4): 330-337. doi:10.1080/15569527.2019.1614020 [79] Jonas JB, Monés J, Glacet-Bernard A, et al. Retinal vein occlusions[J]. Dev Ophthalmol, 2017, 58: 139-167. doi:10.1159/000455278 [80] 唐慧新, 李景景, 邹红. 阈值下微脉冲激光光凝作用机制及临床应用[J]. 山东大学耳鼻喉眼学报,2023,37(3): 143-148. doi:10.6040/j.issn.1673-3770.0.2022.254 TANG Huixin, LI Jingjing, ZOU Hong. GuidanceMechanism and clinical applications of subthreshold diode micropulse laser[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023,37(3): 143-148. doi:10.6040/j.issn.1673-3770.0.2022.254 [81] Terashima H, Hasebe H, Okamoto F, et al. Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result[J]. Retina, 2019, 39(7): 1377-1384. doi:10.1097/IAE.0000000000002165 [82] Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases[J]. Retina, 1999, 19(1): 1-5. doi:10.1097/00006982-199901000-00001 [83] Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases[J]. Retina, 2001, 21(5): 408-415. doi:10.1097/00006982-200110000-00002 [84] Chuang LH, Wang NK, Chen YP, et al. Vitrectomy and panretinal photocoagulation reduces the occurrence of neovascular glaucoma in central retinal vein occlusion with vitreous hemorrhage[J]. Retina, 2013, 33(4): 798-802. doi:10.1097/IAE.0b013e31826af52d [85] DeCroos FC, Shuler RK Jr, Stinnett S, et al. Pars Plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion[J]. Am J Ophthalmol, 2009, 147(4): 627-633.e1. doi:10.1016/j.ajo.2008.10.024 [86] Khan FA, Qureshi NA. Pars Plana vitrectomy for resistant cystoid macular edema[J]. J Coll Physicians Surg Pak, 2019, 29(12): 1165-1168. doi:10.29271/jcpsp.2019.12.1165 [87] Kuo JZ, Lai CC, Ong FS, et al. Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality[J]. Retina, 2010, 30(3): 479-484. doi:10.1097/IAE.0b013e3181b9b3a0 [88] Zhang XT, Zhong YF, Xue YQ, et al. Clinical features of central retinal vein occlusion in young patients[J]. Ophthalmol Ther, 2022, 11(4): 1409-1422. doi:10.1007/s40123-022-00534-7 [89] Koh YY, Lai CC, Wu WC, et al. Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2020, 258(7): 1367-1377. doi:10.1007/s00417-020-04679-8 |
| [1] | TANG Huixin, LI Jingjing, ZOU Hong. Mechanism and clinical applications of subthreshold diode micropulse laser [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 143-148. |
| [2] | GU Ranran, LI Fengjiao, JIAO Wanzhen, CUI Yanyan, ZHAO Bojun. Clinical efficacy of lecithin complex iodine capsule in the adjuvant treatment of retinal vein occlusion [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 46-50. |
| [3] | Keyang HAN,Beibei YU,Bojun ZHAO. Morphological structure analysis of the macular area after anti-VEGF treatment for short-term retinal vein occlusion [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 129-131. |
| [4] | LIANG Qianqian, YANG Tinghua, ZHAO Bojun. Application of optical coherence tomography angiography in retinal vein occlusion [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 139-142. |
| [5] | . Clinical observation on the treatment of BRVO-ME by the combination of laser therapy with Ranibizumab intravitreal injection. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 110-113. |
| [6] | . The pathogenesis of RVO and anti-VEGF treatment for its macular edema. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 123-126. |
| [7] | YAN Xiaoteng, FENG Jun, KANG Xinle. Intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 105-108. |
| [8] | XING Kai, KANG Zefeng. Clinical analysis on intravitreal injection of conbercept in the treatment of macular edema secondary to branch retinal vein occlusion. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(1): 80-82. |
| [9] | WANG Yin-yan, LI Lu-lu, TAO Yu, SHEN Jia-quan. Characteristics of 535 cases of glaucoma in outpatient department [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(3): 56-59. |
| [10] | YAN Xiao-teng， KANG Jian-fang， FENG Jun. Early laser photocoagulation combined with triamcinolone acetonide in treating macular edema secondary to temparal branch retinal vein occlusion [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 75-76. |
| [11] | WANG Yong-bo， SHI An-na， SHI Xun， JIN Yu， LIU Wei-feng. Relationship between photoreceptor cell layer and best corrected visual acuity (BCVA) in patients with retinal vein occlusion [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(1): 78-80. |
| [12] | WANG Shu-ya, HUA Ning, LI Xiao-rong. Causes of blindness after vitreoretinal surgery for proliferative diabetic retinopathy [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2011, 25(6): 77-79. |
| [13] | LI Jin-qi1, WANG Jing-bo2, ZHAO Jing1. Clinical observation of RVO treated with combined Chinese herbs and laser coagulation [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2010, 24(5): 62-. |
| [14] | WANG Lin, GUAN Juan, ZHOU Li, SHENG Yu, SI Yanfang, ZHAO Huiying, ZHAO Juan. Correlation between hyperlipidemia and incidence of retinal vein occlusion [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2010, 24(01): 44-46. |
|
||